Close Menu

Piper Jaffray

The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.

The bank believes investors are too focused on the potential of PacBio's merger with Illumina falling through rather than recent developments regarding its technology.

The genetic testing firm has entered into an equity distribution agreement with Piper Jaffray to offer up to $30 million in stocks, with an initial offering of $22.5 million.

The investment bank cited management confidence in US and European test growth as meriting the upgrade, which was necessary to maintain a current $72 price target on the firm's stock.

An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020.

The analyst said Myraid's GeneSight and NIPT products present near-term opportunities that "should help power earnings upside in the years to come."

The bank said Natera's SNP-based NIPT technology would give it an advantage as it seeks to gain share in the average-risk pregnancy market. 

NEW YORK (GenomeWeb) – Piper Jaffray and Mizuho Securities today initiated coverage of transplant molecular diagnostics firm CareDx with bullish views of the company's stock and market opportunities for its tests.

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray on Thursday initiated coverage of Veracyte with an overweight rating on the firm's stock and a $21 price target.

NEW YORK (GenomeWeb Daily News) — Speaking at Piper Jaffray's annual healthcare conference today, members of Qiagen's management team provided investors with a recap of recent business activities and a glimpse of what's to come.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.